Nivolumab Ipilimumab Combination Outperforms Tyrosine Kinase Inhibitors in Unresectable Hepatocellular Carcinoma
Patients with unresectable hepatocellular carcinoma reported better results with nivolumab ipilimumab....
Patients with unresectable hepatocellular carcinoma reported better results with nivolumab ipilimumab....
Nivolumab plus ipilimumab (NIVO + IPI) is the first-line treatment for patients with metastatic renal cell carcinoma (mRCC). While approximately 40% of patients treated with NIVO + I...
This study aimed to construct an m6A and cuproptosis-related long non-coding RNAs (lncRNAs) signature to accurately predict the prognosis of kidney clear cell carcinoma (KIRC) patients using...
About 20% of patients with renal cell carcinoma present with non-clear cell histology (nccRCC), encompassing various histological types. While surgery remains pivotal for localized-stage ncc...
1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with an HR 0.62 (significant). 2. Adverse events grade 3 or higher occurred in 18.6%...
1. Pazopanib did not improve disease-free survival in post-metastasectomy renal cell carcinoma patients 2. There was a concerning trend favouring placebo when assessing overall survival, su...
Single-cell and spatial transcriptome sequencing, two recently optimized transcriptome sequencing methods, are increasingly used to study cancer and related diseases. Cell annotation, partic...
To describe the impact of a multidisciplinary tumor board (MTB) for renal cell carcinoma (RCC) patients in a locoregional renal cancer network by evaluating shared decision making (SDM) and ...
Primary tumor removal by cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma patients has been investigated in the context of various treatment regimens. Two randomized ...
Accurate diagnosis and treatment of kidney tumors greatly benefit from automated solutions for detection and classification on MRI. In this study, we explore the application of a deep learni...
To investigate impact of body mass index (BMI) on survival across different histologies and stages of renal cell carcinoma (RCC).We conducted a retrospective multicenter analysis of clear ce...
Kidney transplant recipients (KTRs) face an increased risk of renal cell carcinoma (RCC), in which the immunosuppressive regimen plays an important role. This study aimed to identify intrace...
To compare the outcomes of patients undergoing Retroperitoneal laparoscopic Radical nephrectomy (RLRN) and Transperitoneal laparoscopic Radical nephrectomy (TLRN).A total of 120 patients wit...
Surgical treatment for renal cell carcinoma (RCC) and inferior vena cava (IVC) tumor thrombus (TT) is difficult, and the postoperative complication rate is high. This study aimed to explore ...
There is currently no well-accepted consensus on the association between gut microbiota and the response to treatment of immune checkpoint inhibitors (ICIs) in patients with advanced cancer....
The emerging evidence suggested that senescence regulator genes were involved in multi cancers, which may be utilized as new targets for cancers. However, the dysregulation and clinical impa...
Renal cell carcinoma (RCC) is a common primary tumor of the kidney and is divided into three major subtypes, of which clear cell renal cell carcinoma (ccRCC) has the highest incidence. Gluta...
Renal cell carcinoma is the predominant histological type of kidney cancer with historically poor patient outcomes. Lenvatinib in combination with pembrolizumab is an approved first-line reg...
In this prospective cross-sectional clinical study, we aimed to determine the efficiency of preoperative hematological markers namely SIRI (systemic inflammatory response index) and SII (sys...
In this study, we elucidate if synthetic contrast enhanced computed tomography images created from plain computed tomography images using deep neural networks could be used for screening, cl...
The latest articles and insights from your colleagues in your specialty(ies) of choice.
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.